共 50 条
- [31] FINAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF SUNITINIB PLUS FOLFIRI VS. PLACEBO PLUS FOLFIRI IN FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)ANNALS OF ONCOLOGY, 2010, 21 : 19 - 19Carrato, A.Swieboda-Sadlej, A.Staszewska-Skurczynska, M.Lim, R.Roman, L.Shparyk, Y.Bondarenko, I.Lin, X.Lechuga, M. J.Tursi, J. M.Sun, Y.De la Cruz, J. A.Jonker, D.Van Cutsem, E.
- [32] RAINBOW-Asia: A randomized, multicenter, double-blind, phase III study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line chemotherapy with platinum and fluoropyrimidine.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)Xu, Rui-huaZhang, Yan-QiaoPan, HongmingFeng, Ji FengZhang, TaoLiu, TianshuQin, YanruHan, RubingZhang, WanliShen, Lin
- [33] Apatinib plus paclitaxel versus placebo plus paclitaxel as second-line therapy in patients with gastric cancer with peritoneal carcinomatosis: A double-blind, randomized phase II trial.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Wang, FenghuaRen, ChaoXu, JianyingWang, ZhiqiangHe, Ming-mingQiu, MiaozhenJin, YingLuo, HuiyanWang, FengLi, YuhongTan, QiongZhang, RongXu, Ruihua
- [34] Phase III study of vinflunine plus gemcitabine versus paclitaxel plus gemcitabine in the first-line treatment of anthracycline pretreated advanced breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Llombart, AntonioEspie, MarcRanade, AnantbhushanTrukhin, DmytroHegg, RobertoDel Giglio, AuroParidaens, RobertStaroslawska, ElzbietaVeyret, CorinneSakaeva, DinaGomez, Henry LeonidasLokanatha, DasappaLerzo, Guillermo LuisShewalkar, Balaji KeshavraoTalbot, Denis CharlesSantoro, ArmandoRoche, Henri Hubert
- [35] A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinomaCANCER, 2000, 88 (01) : 124 - 131Perez, EAHillman, DWStella, PJKrook, JEHartmann, LCFitch, TRHatfield, AKMailliard, JANair, SKardinal, CGIngle, JN
- [36] Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational studyANNALS OF ONCOLOGY, 2016, 27 (09) : 1725 - 1732Delaloge, S.Perol, D.Courtinard, C.Brain, E.Asselain, B.Bachelot, T.Debled, M.Dieras, V.Campone, M.Levy, C.Jacot, W.Lorgis, V.Veyret, C.Dalenc, F.Ferrero, J. M.Uwer, L.Kerbrat, P.Goncalves, A.Mouret-Reynier, M. A.Petit, T.Jouannaud, C.Vanlemmens, L.Chenuc, G.Guesmia, T.Robain, M.Cailliot, C.
- [37] Preliminary results of a phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancerMOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3591S - 3591SKozloff, MarkChuang, EllenRoy, JessicaStarr, AlexanderGowland, Patricia A.Tarpey, Matthew J.Collier, MaryVerkh, LevKern, KennethMiller, Kathy
- [38] Preliminary results of a phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancerEJC SUPPLEMENTS, 2007, 5 (04): : 216 - 216Kozloff, M.Chuang, E.Roy, J.Starr, A.Gowland, P. A.Tarpey, M. J.Collier, M.Verkh, L.Kern, K.Miller, K.
- [39] A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)Bendell, Johanna C.Hochster, Howard S.Hart, Lowell L.Firdaus, IrfanMace, Joseph RonaldMcFarlane, Joshua JemisonKozloff, MarkCatenacci, Daniel Virgil ThomasHsu, Jessie J.Hack, Stephen PaulShames, David S.Phan, See-ChunCohn, Allen Lee
- [40] An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancerANNALS OF ONCOLOGY, 2010, 21 (07) : 1436 - 1441Kozloff, M.Chuang, E.Starr, A.Gowland, P. A.Cataruozolo, P. E.Collier, M.Verkh, L.Huang, X.Kern, K. A.Miller, K.